SeaStar Medical Holding Corporation: Fourth Quarter and Year-End 2024 Financial Results and Business Update
Denver, CO – March 24, 2025 – SeaStar Medical Holding Corporation (NASDAQ: ICU), a pioneering healthcare company dedicated to revolutionizing treatments for critically ill patients confronting organ failure and the prospect of imminent death, announced today that it will release its financial results for the fourth quarter and full year ending December 31, 2024, following market close on Thursday, March 27, 2025. The company will then host a webcast and conference call to discuss the financial results and provide updates on its business progress.
Company Background
SeaStar Medical Holding Corporation, based in Denver, Colorado, is a commercial-stage healthcare company that has been making significant strides in the critical care market. The company focuses on developing and commercializing innovative medical technologies designed to transform treatments for critically ill patients. SeaStar’s mission is to save lives and improve patient outcomes by addressing the unmet needs in critical care.
Fourth Quarter and Year-End 2024 Financial Results
Investors and interested parties are invited to listen to a live webcast of the conference call, which will be accessible on the company’s website at
Business Progress Update
During the conference call, SeaStar Medical’s management team will discuss the company’s business progress, including updates on its product pipeline and commercialization efforts. SeaStar’s portfolio includes the HemoClear Hemodialysis Filter, a novel micro-porous filter that addresses the limitations of conventional hemodialysis filters, and the HemoClear Hemofilter, a high-performance, low-volume hemofilter for the removal of toxins and excess fluids in critically ill patients. The company has also recently announced the initiation of a pivotal trial for its HemoClear Hemofilter, which is expected to provide data supporting its regulatory submission in the United States and Europe.
Impact on the Individual
For critically ill patients, every second counts. The innovative technologies developed by SeaStar Medical Holding Corporation have the potential to significantly improve patient outcomes and save lives. The release of the company’s financial results and business update on March 27, 2025, will provide investors with valuable insights into the company’s progress and future prospects. As a shareholder, this information can help inform investment decisions and assess the potential impact on the value of your investment in SeaStar Medical.
Impact on the World
The critical care market is a growing sector, driven by the increasing global population and the rising prevalence of chronic diseases. SeaStar Medical Holding Corporation’s focus on developing and commercializing innovative medical technologies to address the unmet needs in this market can lead to significant advancements in the treatment of critically ill patients. The successful commercialization of SeaStar’s products could potentially save countless lives and improve patient outcomes, making a significant impact on the global healthcare landscape.
Conclusion
SeaStar Medical Holding Corporation’s announcement of its fourth quarter and year-end 2024 financial results and business update on March 27, 2025, represents an important milestone for the company and the critical care market. As a shareholder, this information is crucial for making informed investment decisions. For the global community, SeaStar’s advancements in medical technologies have the potential to revolutionize the treatment of critically ill patients and save lives. Stay tuned for further updates from SeaStar Medical Holding Corporation.
- SeaStar Medical Holding Corporation to report fourth quarter and year-end 2024 financial results on March 27, 2025.
- Webcast and conference call to discuss financial results and business progress.
- Company focuses on developing and commercializing innovative medical technologies for critically ill patients.
- Impactful updates on product pipeline and commercialization efforts.
- Pivotal trial initiation for HemoClear Hemofilter.
- Potential to significantly improve patient outcomes and save lives.
- Important milestone for SeaStar Medical Holding Corporation and the critical care market.
